A Study of mDOT for Immunosuppressant Adherence in Solid Organ Transplant Recipients
Medication Adherence · Liver Transplantation · Kidney Transplantation
Bottom Line
View on ClinicalTrials.gov: NCT04587024 ↗Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- mHealth intervention (Other); standard of care (Other)
- Age
- Pediatric, Adult, Older Adult · 13+ yrs
- Sex
- All
- Sponsor
- Johns Hopkins University
- Primary completion
- Aug 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Medication Adherence Via Medication Level Variability Index (MLVI) |
23; 24; 10; 8; 3; 2 | — |
| SECONDARY Blood Tacrolimus Levels |
2.6; 2.37 | — |
| SECONDARY Patient Reported Adherence |
12; 11 | — |
| SECONDARY Patient Reported QoL as Assessed by the PedsQL |
— | — |
| SECONDARY mHealth Usability Measurement |
1.57 | — |
| SECONDARY Patterns of Medication Adherence |
— | — |
| SECONDARY Provider Workflow as Assessed by Patient Usage of the mDOT App |
— | — |
| SECONDARY Patient Reported QoL as Assessed by the SF-36 |
— | — |
Summary
Eligibility Criteria
Inclusion Criteria
Participants must meet all of the following inclusion criteria to participate in this study:
> 13 years old Own a smart phone and are willing to receive information through it Received a liver or kidney transplant at a participating study site during or prior to the study period.
Exclusion Criteria
All candidates meeting any of the following exclusion criteria at baseline will be excluded from study participation:
Patients with cognitive impairments will not be eligible for enrollment due to inability to provide informed consent.
Inability or unwillingness of individual or legal guardian/representative to give consent.
Data sourced from ClinicalTrials.gov (NCT04587024). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.